These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24618438)

  • 41. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
    Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
    Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The ultimate biochemical diagnosis of neuroendocrine gastro-enteropancreatic tumours.
    Faiss S; Scherübl H; Riecken EO; Wiedenmann B
    Digestion; 1996; 57 Suppl 1():48-9. PubMed ID: 8813469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
    Bao F; Chen GR; Hui P; Cai GP
    Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
    [No Abstract]   [Full Text] [Related]  

  • 44. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature.
    Patel FB; Khagi S; Daly KP; Lechan RM; Ummaritchot V; Saif MW
    Anticancer Res; 2013 Sep; 33(9):4001-5. PubMed ID: 24023341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. False-Positive Pancreastatin Results From a Commercial Laboratory: A Report of 2 Cases.
    Sagum J; Yu R
    Pancreas; 2021 Mar; 50(3):e33-e35. PubMed ID: 33835984
    [No Abstract]   [Full Text] [Related]  

  • 49. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
    Ali S; Cohen C; Little JV; Sequeira JH; Mosunjac MB; Siddiqui MT
    Diagn Cytopathol; 2007 Oct; 35(10):644-8. PubMed ID: 17854080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.
    Uccella S; La Rosa S; Volante M; Papotti M
    Endocr Pathol; 2018 Jun; 29(2):150-168. PubMed ID: 29520563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnosis of neuroendocrine tumours in the gastrointestinal tract].
    Rehfeld JF; Friis-Hansen L; Gøtze JP; Hilsted L; Nielsen FC
    Ugeskr Laeger; 2010 Oct; 172(43):2957-60. PubMed ID: 21040675
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.
    Hackeng WM; Dreijerink KMA; de Leng WWJ; Morsink FHM; Valk GD; Vriens MR; Offerhaus GJA; Geisenberger C; Brosens LAA
    Clin Cancer Res; 2021 Mar; 27(5):1341-1350. PubMed ID: 33355250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer.
    Paik WH; Song BJ; Kim HW; Kim HR; Hwang JH
    Korean J Gastroenterol; 2015 Oct; 66(4):215-20. PubMed ID: 26493507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Diagnosis of pancreatic neuroendocrine tumor and medical treatment of endocrine symptoms].
    Takano K
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():363-7. PubMed ID: 25857049
    [No Abstract]   [Full Text] [Related]  

  • 56. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
    Jiang R; Hong X; Zhao Y; Wu W
    Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
    Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
    Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
    Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
    How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
    Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.